
Commentary|Videos|May 31, 2024
CMSC Live: 2024 Annual Meeting Day 3
Host Jeffrey Wilken, PhD, chats with Marijean Buhse, PhD, RN, NP-C, MSCN; Amy Sullivan, PsyD, ABPP; and John DeLuca, PhD, ABPP, FACRM, FAPA, FAPS, FNAN, about the third day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.
Advertisement
Host
- Jeffrey Wilken, PhD
President-Elect, Consortium of Multiple Sclerosis Centers (CMSC); assistant professor of neurology, Georgetown University; director of Research, Neuropsychology Associates of Fairfax; executive director, Washington Neuropsychology Research Group
Guests
- Marijean Buhse, PhD, RN, NP-C, MSCN
Clinical Professor of Graduate Studies/Advanced Practice Nursing; Program Director, Doctor of Nursing Practice, Stony Brook School of Nursing - Amy Sullivan, PsyD, ABPP
Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine; Director, Neurological Institute Engagement and Well-being; Director of Behavioral Medicine & Research, Mellen Center for MS; Chair, Neurological Institute Engagement and Women’s Leadership Development Cleveland Clinic - John DeLuca, PhD, ABPP, FACRM, FAPA, FAPS, FNAN
Senior Vice President for Research and Training at Kessler Foundation; Professor in the Department of Physical Medicine & Rehabilitation and the Department of Neurology, Rutgers New Jersey Medical School
Segment Breakdown
- 00:00 – Marijean Buhse, PhD, RN, NP-C, MSCN, discusses her panel presentation on multidisciplinary NMOSD care, the need for better definition of patient-reported outcomes in MS, and her presentation on MS aging and the conversation about stopping disease-modifying therapy.
- 09:51 – Amy Sullivan, PsyD, ABPP, talks about the ability to reconnect with colleagues at CMSC, Francios Bethoux's talk on art as a therapeutci medicine in MS, her presentation on stress management tools in MS, empowering women in leadership roles in medicine, and the need to better address burnout among physicians.
- 00:00 – John DeLuca, PhD, ABPP, FACRM, FAPA, FAPS, FNAN, speaks about being inducted into the 2024 class of Giants of MS, his symposium of addressing and defining fatigue in clinical care, the failure of pharmacotherapy for cognitive challenges in MS, and the lack of clinical application of cognitive rehabiliation tools despite the thorough and exisiting literature supporting its use.
Advertisement
Related to this article

The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.

The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.

5-year findings from the Clarity AD long-term extension, presented at CTAD 2026, showed progressively greater differences in CDR-SB outcomes compared with external natural history cohorts.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Venglustat as First Therapy for Neurological Manifestations of Type 3 Gaucher Disease
2
FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis
3
Phase 2 SPINOZA Trial to Test CETP Inhibitor Obicetrapib in APOE-Stratified Preclinical Alzheimer Disease
4
ALS Prevention, Gene Therapy, and Newborn Screening at MDA 2027
5


